← Back to patent-cliff list
CAS 866607-35-4
(2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
Codes: CANA-015
Application context (from source-drug indications)
End-stage renal diseaseCanagliflozin/Metformin HydrochlorideCardiac and vascular disordersCanagliflozin/Metformin HydrochlorideAbdominal aortic aneurysmCanagliflozin/Metformin HydrochlorideType 2 diabetesCanagliflozin/Metformin HydrochlorideType 2 diabetesCanagliflozin HemihydrateDiabetic nephropathyCanagliflozin HemihydrateCoronary artery lesionCanagliflozin HemihydrateDiabetesCanagliflozin HemihydrateHeart failureCanagliflozin HemihydrateEnd-stage renal diseaseCanagliflozin Hemihydrate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Canagliflozin/Metformin Hydrochloride | Tier B — Position early | 2029 |
| Canagliflozin Hemihydrate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2-(4-fluorophenyl)thiophene→2-bromothiophene→1-bromo-4-fluorobenzene→5-iodo-2-methylbenzoyl chloride→2-(4-fluorophenyl)-5-(5-iodo-2-methylbenzyl)thiophene→(2R,3R,4S,5R)-2-(acetoxymethyl)-6-oxotetrahydro-2H-pyran-3,4,5-triyl triacetate→(3R,4S,5R,6R)-6-(acetoxymethyl)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-2-hydroxytetrahydro-2H-pyran-3,4,5-triyl triacetate→(2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
2-(4-fluorophenyl)thiophene→2-bromothiophene→1-bromo-4-fluorobenzene→5-iodo-2-methylbenzoyl chloride→2-(4-fluorophenyl)-5-(5-iodo-2-methylbenzyl)thiophene→(2R,3R,4S,5R)-2-(acetoxymethyl)-6-oxotetrahydro-2H-pyran-3,4,5-triyl triacetate→(3R,4S,5R,6R)-6-(acetoxymethyl)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-2-hydroxytetrahydro-2H-pyran-3,4,5-triyl triacetate→(2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | (1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4methylphenyl]-D-glucitol tetraacetate Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.